FDA Adverse Event Injury Summary report: N

XIENCE V EVEROLIMUS ELUTING CORONARY STENT SYSTEM

MDR report key: 1231635 · Received November 14, 2008

Report

Report Number
2024168-2008-01155
Event Type
Injury
Date Received
November 14, 2008
Date of Event
September 26, 2008
Report Date
October 15, 2008
Manufacturer
ABBOTT VASCULAR-CARDIAC THERAPIES
Product Code
NIQ
PMA / PMN Number
P070015
Removal / Correction Number
NA
Adverse Event
Yes
Report Source
Manufacturer report
Reporter Location
IT
Reporter Occupation
PHYSICIAN

Narratives

Additional Manufacturer Narrative · 1

RESULTS AND CONCLUSION SUMMATION: PRODUCT PERFORMANCE ENGINEERING REVIEWED THE INCIDENT. DISSECTION, LISTED IN THE XIENCE IFU, IS A KNOWN ADVERSE EVENT ASSOCIATED WITH CORONARY STENTING AND IS NOT AN INDICATION OF A PRODUCT QUALITY ISSUE. THERE WAS NO REPORT OF A DEVICE MALFUNCTION. DISSECTION CAN BE INFLUENCED BY LESION CHARACTERISTICS, PROCEDURAL TECHNIQUE, AND DEVICE SIZE SELECTION. THE IFU STATES, "IMPLANTING A STENT MAY LEAD TO DISSECTION OF THE VESSEL DISTAL AND/OR PROXIMAL TO THE STENT AND MAY CAUSE ACUTE CLOSURE OF THE VESSEL REQUIRING ADDITIONAL INTERVENTION (CABG, FURTHER DILATATION, PLACEMENT OF ADDITIONAL STENTS, OR OTHER)." A CONCLUSIVE ROOT CAUSE FOR THE PATIENT EFFECT, AND RELATIONSHIP TO THE DEVICE, CANNOT BE DETERMINED.

Description of Event or Problem · 1

REPORTING STATUS: SERIOUS INJURY/MEDICAL INTERVENTION. REPORTING RATIONALE: DISSECTION. DEVICE ISSUE: NO DEVICE MALFUNCTION HAS BEEN REPORTED. IT WAS REPORTED VIA TRIAL THAT THE PATIENT WAS EXPERIENCING ANGINA. PRE-DILATATION WAS PERFORMED IN THE PROX LAD. DURING DEPLOYMENT OF THE FIRST XIENCE V STENT IN THE PROXIMAL LAD, A DISSECTION OCCURRED DISTAL TO THE TARGET LESION. ANTHER XIENCE V STENT WAS USED AS A BAILOUT STENT, AND THE DISSECTION WAS TREATED SUCCESSFULLY. NO ADDITIONAL EVENT OR PATIENT INFORMATION IS AVAILABLE.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
1 XIENCE V EVEROLIMUS ELUTING CORONARY STENT SYSTEM NIQ ABBOTT VASCULAR-CARDIAC THERAPIES NA UNK

Patients

Seq Age Sex Outcome Treatment
1 55 YR Required Intervention